This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Business News at 5:30 p.m.
The supervisor is Richard Jacobsen (800-845-8450, ext. 1680). For photos, ext. 1900. For graphics and interactives, ext. 7636. Expanded AP content can be obtained from http://www.apexchange.com. For access to AP Exchange and other technical issues, contact customersupport(at)ap.org or call 877-836-9477.
If you have questions about transmission of financial market listings, please call 800-3AP-STOX.
A selection of top photos can be found at http://bit.ly/APTopPhotos
NEW THIS DIGEST:
â¿¿ Adds: BRITAIN-ECONOMY, APPLE-INVESTORS
â¿¿ Updates: WALL STREET
BOEING 787-BATTERY FIX
WASHINGTON â¿¿ Boeing took a major step toward getting its 787 "Dreamliners" flying again, proposing a fix for the plane's troubled batteries that could allow flights to resume as early as April, congressional officials say. The next question is whether the Federal Aviation Administration will agree to a plan that appears focused on containing a fire and let the planes fly even though the root cause of the battery problems isn't yet known. By Joan Lowy and Joshua Freed.
â¿¿ JAPAN-BOEING 787 â¿¿ Japanese authorities have identified the causes of fuel leaks and other problems with Boeing's 787 but are still investigating the more serious battery problem that forced an emergency landing in January and the worldwide grounding of the jets.
NEW YORK â¿¿When the top executives of the world's wireless industry gather next week in Barcelona for their annual trade show, cellphones will be taking a back seat to discussion of cars, electric meters and insulin monitors. Now that most people have cellphones, the industry is looking to connect other devices to keep growth going. Organizers expect record attendance for the show and a boost to Barcelona's struggling economy. By Technology Writer Peter Svensson.
BREAST CANCER DRUG-ROCHE
WASHINGTON â¿¿ The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. Cancer researchers say the drug may offer a clear advantage over older drugs because it delivers more medication with fewer side effects. By Business Writer Matthew Perrone.